A prediction model and risk stratification tool for survival by chemotherapy in invasive micropapillary carcinoma of the breast: a population-based study with external validation - Summary - MDSpire
Advertisement
A prediction model and risk stratification tool for survival by chemotherapy in invasive micropapillary carcinoma of the breast: a population-based study with external validation
To identify patients with invasive micropapillary carcinoma (IMPC) who are most likely to benefit from chemotherapy and to develop a risk-stratified prediction model to optimize treatment decisions.
Key Findings:
Chemotherapy was associated with significantly improved overall survival (OS) in the SEER cohort (HR = 0.517, 95% CI 0.293-0.910, P = 0.020).
No significant association was found between chemotherapy and breast cancer-specific survival (BCSS).
The risk model identified high- and low-risk groups, with chemotherapy improving OS primarily in high-risk patients.
Interpretation:
Chemotherapy may improve prognosis in high-risk IMPC patients, but its benefits in low-risk patients are uncertain and should be approached cautiously, emphasizing the need for careful patient selection.
Limitations:
The study is retrospective and may have inherent biases that could affect the validity of the findings.
The external validation cohort may not fully represent the broader IMPC population.
Conclusion:
Chemotherapy is associated with improved prognosis in high-risk IMPC patients, necessitating careful consideration for low-risk patients.
